Patents Issued in November 2, 2017
  • Publication number: 20170312231
    Abstract: The present document describes a method of preventing or treating a hoof bacterial infection on at least one hoof of a live hoofed animal having a bacterial presence thereon with an antibacterial formulation comprising: a) at least one antimicrobial isolated or synthetic phenolic compound of natural origin; b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in water; c) a solvent for dissolving said phenolic compound; and d) a sufficient water quantity to make 100% (w/w).
    Type: Application
    Filed: July 19, 2017
    Publication date: November 2, 2017
    Inventors: Gaetan LEMIRE, Ulysse DESRANLEAU DANDURAND, Sylvain QUESSY, Ann LETELLIER
  • Publication number: 20170312232
    Abstract: Provided herein are methods and compositions for use in the treatment of depression, anxiety or a depressive or anxiety-related disorder. Embodiments describe the administration of orotic acid or a salt thereof, or the administration of one or more probiotic microorganisms, or administration of a combination of orotic acid or a salt thereof and one or more probiotic microorganisms.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 2, 2017
    Inventors: Luis Vitetta, Samantha Maree Coulson, Sean Hall
  • Publication number: 20170312233
    Abstract: Provided herein are pharmaceutical compositions and methods of treating cancer wherein the cytotoxic activity of an anticancer agent is potentiated by the combination of base excision repair (BER) pathway inhibitors.
    Type: Application
    Filed: July 12, 2017
    Publication date: November 2, 2017
    Inventor: Charles Theuer
  • Publication number: 20170312234
    Abstract: The present invention provides a pharmaceutical composition including a therapeutically efficient amount of a compound represented by formula (1), at least an anticancer agent, and a pharmaceutically acceptable carrier. The present invention further provides a use of the compound represented by formula (1) for the manufacture of a medicament for treating hepatocellular carcinoma.
    Type: Application
    Filed: May 2, 2016
    Publication date: November 2, 2017
    Applicant: National Taiwan Normal University
    Inventor: Jung-Yaw Lin
  • Publication number: 20170312235
    Abstract: The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinapathy, thalassemia and aplastic anemia.
    Type: Application
    Filed: February 9, 2017
    Publication date: November 2, 2017
    Inventors: Susan Park PERRINE, Douglas V. Faller
  • Publication number: 20170312236
    Abstract: The present invention relates to a pharmaceutical composition comprising flurbiprofen and tramadol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 2, 2017
    Inventors: ALI TÜRKYILMAZ, NUR PEHLIVAN AKALIN, DENIZ DURGUN, BASAK YIGITER
  • Publication number: 20170312237
    Abstract: Described herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, or combinations thereof, as well as uses thereof. Such uses include promoting tissue self-repair or tissue regeneration of an organ, stimulating the generation of tissue growth, modulating (e.g. increasing) the level of a tissue-repair marker, treating physical injury in an organ, tissue, or cell, promoting wound healing as well as anti-aging applications. Corresponding compositions, methods and uses are also described. Formula I wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F of OH; R2 is H, F, OH, C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH, or CH2Ph; R4 is H, F or OH; Q is 1) (CH2),C(O)OH wherein m is 1 or 2 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH or 6) C(O)—C(O)OH.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 2, 2017
    Inventors: Lyne GAGNON, Pierre LAURIN
  • Publication number: 20170312238
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventor: Brendan Lee
  • Publication number: 20170312239
    Abstract: The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
    Type: Application
    Filed: December 13, 2016
    Publication date: November 2, 2017
    Inventors: Giancarlo Naccari, Sergio Baroni
  • Publication number: 20170312240
    Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
    Type: Application
    Filed: May 15, 2017
    Publication date: November 2, 2017
    Inventors: Michael Zemel, E. Douglas Grindstaff, II, Antje Bruckbauer
  • Publication number: 20170312241
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20170312242
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20170312243
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 2, 2017
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20170312244
    Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
    Type: Application
    Filed: July 30, 2015
    Publication date: November 2, 2017
    Applicant: DAE HWA PHARMA. CO., LTD.
    Inventors: In-Hyun LEE, Min-Hee SON, Yeong-Taek PARK, Seul-Ae LEE, Han-Koo LEE
  • Publication number: 20170312245
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Publication number: 20170312246
    Abstract: Provided herein are lipidic furan, pyrrole, and thiophene compounds, compositions, and methods using such compounds and compositions for the treatment of atrophic vaginitis. Specifically, the invention includes administering an effective amount of a compound of Formula I, I?, or I?, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from atrophic vaginitis.
    Type: Application
    Filed: April 27, 2017
    Publication date: November 2, 2017
    Applicant: Avoscience, LLC
    Inventor: Richard Huber
  • Publication number: 20170312247
    Abstract: The present invention is related to an active substance of Hericium erinaceus having a pain-relieving effect, and a pharmaceutical composition including the active substance. The active substance is prepared using the following steps: (a) inoculating a mycelium of H. erinaceus on an agar plate and incubating at 15-32° C. for 8-16 days; (b) inoculating the incubated H. erinaceus mycelia from step (a) into a medium in a flask and incubating at 20-30° C. and pH 4.5-6.5 for 3-5 days; (c) inoculating the incubated H. erinaceus mycelia from step (b) into a medium in a fermentation tank and incubating at 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the H. erinaceus mycelia; and (d) desiccating the fermented medium of the H. erinaceus mycelia from step (c) to obtain the powder of the H. erinaceus mycelia, which is further purified and isolated to obtain a novel compound of H. erinaceus.
    Type: Application
    Filed: September 2, 2015
    Publication date: November 2, 2017
    Applicant: GRAPE KING BIO LTD.
    Inventors: Pei-Shan Liu, Chien-Chih Chen, Chin-Chu Chen, Li-Ya Lee, Wan-Ping Chen, Ting-Wei Lin, Jui-Hsia Hsu, Wei-Ching Chu
  • Publication number: 20170312248
    Abstract: A pharmaceutical composition containing ginkgolide B and an ADP receptor antagonist, a preparation method thereof and use thereof in preparation of antiplatelet drugs, wherein the ADP receptor antagonist is clopidogrel, prasugrel, ticagrelor and/or ticlopidine.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 2, 2017
    Applicant: CHENGDU BAIYU PHARMACEUTICAL CO., LTD
    Inventor: Yi SUN
  • Publication number: 20170312249
    Abstract: The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.
    Type: Application
    Filed: October 8, 2015
    Publication date: November 2, 2017
    Applicants: University of South Australia, Central Adelaide Local Health Network Inc.
    Inventors: Joanna Woodcock, Angel Lopez, Stuart Maxwell Pitson, Michael Susithiran Samuel, Carl Coolen
  • Publication number: 20170312250
    Abstract: Disclosed are melanin compositions and devices, and methods of use thereof, to protect internal tissues and organs from radiation damage and to prevent or alleviate negative side effects associated with radiation exposure.
    Type: Application
    Filed: May 2, 2017
    Publication date: November 2, 2017
    Inventor: Paul Tumpowsky
  • Publication number: 20170312251
    Abstract: The present invention relates to a fertility-enhancing composition for human male fertility therapy and a method for using the same to improve or enhance human male fertility. The nutritional supplement composition of the invention includes an effective amount of L-carnitine tartrate, coenzyme Q10, methylcobalamin, N-acetyl L-cysteine, and grape seed extract.
    Type: Application
    Filed: April 30, 2016
    Publication date: November 2, 2017
    Applicant: Fairhaven Health, LLC
    Inventor: Suzanne Munson
  • Publication number: 20170312252
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 2, 2017
    Inventors: Kwong Wah Lai, Jun Liang, Birong Zhang, Sharada Labadie, Daniel Ortwine, Peter Dragovich, James Kiefer, Victor S. Gehling, Jean-Christophe Harmange
  • Publication number: 20170312253
    Abstract: The present invention belongs to pharmaceutical field, specifically, relates to use of Edaravone in the preparation of a medicament for preventing and treating cerebral amyloid angiopathy (CAA). By administering Edaravone, the present invention could scavenge the deposited amyloid (A?) in the brain and prevent the intracerebral A? deposition.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 2, 2017
    Inventors: Yanjiang WANG, Shusheng JIAO, Xiuqing YAO, Xinfu ZHOU
  • Publication number: 20170312254
    Abstract: This invention provides a low dose pharmaceutical composition comprising deferasirox or a pharmaceutically acceptable derivative thereof and one or more pharmaceutically acceptable excipients. A unit dose of the pharmaceutical composition comprises from about 50 mg to about 100 mg of deferasirox, from about 150 mg to about 200 mg of deferasirox or from about 260 mg to about 350 mg of deferasirox. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox, may be used to treat chronic iron overload or to treat lead toxicity. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox and deferiprone, may be used to treat lead toxicity.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Inventors: Geena MALHOTRA, Shrinivas Madhukar PURANDARE
  • Publication number: 20170312255
    Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 27, 2017
    Publication date: November 2, 2017
    Applicants: Cumberland Pharmaceuticals, Inc., Vanderbilt University
    Inventors: Leo Pavliv, James West, Ines Macias-Perez, Erica Carrier
  • Publication number: 20170312256
    Abstract: Described herein are transdermal parasiticidal formulations and methods of treatment and use, wherein the formulation is not only able to deliver an agent or agents through the skin layer, but is able to do so through wool, dirt and/or a sebum layer on the skin if such layers are present. The transdermal parasiticidal formulation may be a solution including a therapeutically effective amount of levamisole anthelmintic agent dissolved in a solution including isopropyl myristate and D-limonene. This base formulation is highly compatible with other compounds and various other actives may be added to this formulation.
    Type: Application
    Filed: April 12, 2017
    Publication date: November 2, 2017
    Inventor: Karen YERITSYAN
  • Publication number: 20170312257
    Abstract: The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.
    Type: Application
    Filed: May 2, 2017
    Publication date: November 2, 2017
    Inventors: ERIC HOLMES, GARY OSTRANDER
  • Publication number: 20170312258
    Abstract: The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Inventors: Jean C. Sung, Diana Manzanedo, Jason M. Perry, Wesley Dehaan, Brian Trautman
  • Publication number: 20170312259
    Abstract: There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 2, 2017
    Applicant: Chase Pharmaceuticals Corporation
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • Publication number: 20170312260
    Abstract: A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Azelnidipine or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, and skin cancer.
    Type: Application
    Filed: October 23, 2015
    Publication date: November 2, 2017
    Applicant: LAUNX BIOMEDICAL CO., LTD.
    Inventors: Chiu-Hung Chen, Show-Mei Chuang, Tzong-Der Way, Nai-Wan Hsiao
  • Publication number: 20170312261
    Abstract: A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and nicotine during chewing. Methods to provide tobacco and/or cannabis smoking cessation using the chewing gum composition according to this invention are also provided.
    Type: Application
    Filed: April 23, 2017
    Publication date: November 2, 2017
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • Publication number: 20170312262
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 2, 2017
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Publication number: 20170312263
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.
    Type: Application
    Filed: May 23, 2017
    Publication date: November 2, 2017
    Inventors: Jillian Basinger, Graeme Freestone, Varsha Gupta, Alan Kaplan, Chi Ching Mak, Benjamin Pratt, Vincent Santora, Dipanjan Sengupta, Lino Valdez
  • Publication number: 20170312264
    Abstract: The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provides packages, therapeutic packages and pharmaceutical compositions, comprising one or more unit doses of 0.5-1.5 mg laquinimod for treating or delaying disease progression in a subject afflicted with HD. Also disclosed is use of laquinimod in the manufacture of a medicament comprising one or more unit doses of 0.5-1.5 mg laquinimod for use in treating or delaying disease progression in a subject afflicted HD.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anna Kristina Sveinsdotter Teige Wickenberg, Esther Lukasiewicz Hagai, Eli Eyal, Sigal Melamed-Gal
  • Publication number: 20170312265
    Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
    Inventors: Masafumi IHARA, Takakuni MAKI, Akihiko TAGUCHI
  • Publication number: 20170312266
    Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 2, 2017
    Inventors: Zhi-Hong Jiang, Jing-Rong Wang, Cheng-Yu Chen, Guo-Yuan Zhu
  • Publication number: 20170312267
    Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 2, 2017
    Inventors: Zhi-Hong Jiang, Jing-Rong Wang, Cheng-Yu Chen, Guo-Yuan Zhu
  • Publication number: 20170312268
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: February 3, 2017
    Publication date: November 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. Lin, Thamas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Publication number: 20170312269
    Abstract: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an ?-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Application
    Filed: January 20, 2017
    Publication date: November 2, 2017
    Inventors: Anthony A. McKinney, Gary Tollefson, Michael A. Cowley
  • Publication number: 20170312270
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 2, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Publication number: 20170312271
    Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Applicant: Grünenthal GmbH
    Inventors: Judy ASHWORTH, Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
  • Publication number: 20170312272
    Abstract: The present invention relates to a solid pharmaceutical composition of temozolomide that has good and consistent flowability as a powder and taste masking and is readily dispersible in an aqueous solution suitable for oral administration, e.g., as a dry sprinkle. This permits patients and healthcare workers to accurately measure doses.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Inventors: Gary Payton, Jeff Bryant
  • Publication number: 20170312273
    Abstract: The present disclosure relates to methods of treating, preventing or ameliorating a TH17- or CSF1-mediated disease or disorder such as cancer, immunological disorders, and obesity by administering to a patient in need thereof a therapeutically effective amount of a FASN inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
    Type: Application
    Filed: April 25, 2017
    Publication date: November 2, 2017
    Inventors: David S. Millan, Wei Lu
  • Publication number: 20170312274
    Abstract: A method of treating a brain tumour such as glioblastoma in a mammal is provided comprising administering to the mammal a DRD4 antagonist.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 2, 2017
    Inventors: Peter Dirks, Sonam Dolma
  • Publication number: 20170312275
    Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
    Type: Application
    Filed: July 16, 2017
    Publication date: November 2, 2017
    Applicant: Glytech, LLC
    Inventor: Daniel C. Javitt
  • Publication number: 20170312276
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 2, 2017
    Applicant: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Publication number: 20170312277
    Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Inventor: Songzhu An
  • Publication number: 20170312278
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 2, 2017
    Inventors: Kimberly Elizabeth FULTZ, Tam Minh TRAN, Shuichan XU, Weiming XU
  • Publication number: 20170312279
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 2, 2017
    Applicant: Respivert Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Lonshaw
  • Publication number: 20170312280
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: April 27, 2017
    Publication date: November 2, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang